"Robert" <[email hidden]> wrote in message
news:[email hidden]...
Quoted message said:
"Sharon Hope" <[email hidden]> wrote in message
news:[email hidden]...
Quoted message said:Yes, and this is also understood to be the mechanism for cognitive damage
from statin drugs (Lipitor, Crestor, Zocor, Pravachol, Lescol, Mevacor,
and
Quoted message said:Baycol).
Understood mechanism for cognitive damage?
Maybe it's the milk they are drinking?
Here's the proven understood mechanism. The milk causes your lungs to glue
together and causes depletion of oxygen and in so doing your body is
forced
into making ROS causing the damage.
That's been understood for many years now.
Quoted message said:
Statin drugs depelete body of CoQ10, an antioxidant that is normally
manufactured in the body, but statins interrupt that process.
Everybody knows that. There's a million people with muscle damage and
renal
failure and cognitive damage.
Actually, there is measurable evidence of cognitive damage after only 6
months of statin use. See Dr. Muldoon's studies.
Randomized trial of the effects of simvastatin on cognitive functioning in
hypercholesterolemic adults.
Am J Med. 2004 Dec 1;117(11):823-9.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15589485
Effects of lovastatin on cognitive function and psychological well-being.
Am J Med. 2000 May;108(7):538-46.
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=10806282
BTW, CoQ10 affects quite a bit of the body, and a deficiency caused by
statin drugs can impact the body in many ways. See the presentations from
last weekend below:
Programme of the 4th Conference of the International Coenzyme Q10
Association
Beverly Hilton, Los Angeles, April 14-17 2005
Thursday, April 14th
14.00 - 19.00 Registration
19.00 Welcome reception
Friday, April 15th
8.30 - 8.50: Introductory remarks:
Bioenergetics and Biosynthesis
Chairpersons: G. Lenaz and E. Cadenas
8.50 G. Lenaz The existence of supercomplexes of the mitochondrial
respiratory chain:
the role of Coenzyme Q diffusion and implications in human
pathology
9.10 G. Dallner Regulation of coenzyme Q synthesis by endogenous modified
intermediates
9.30 C. Clarke Genetic and Physical Evidence for a Coenzyme Q
Biosynthetic Complex
9.50 J. Olsson Reduction of coenzyme Q10 by thioredoxin reductase. A
reaction
dependent on the selenium concentration.
10.10 - 10.30 Discussion
10.30 - 10.50 Coffee break
10.50 P. Navas Q biosynthesis during development and aging
11.10 M. Kawamukai Prenyl diphosphate synthases from higher eukaryotes
11.30 - 11.40 Discussion
Non mitochondrial electron transport and antioxidant
aspects
Chairpersons: T. Kishi and L. Packer
11.40 T. Kishi Extra-mitochndrial CoQ redox cycle and cellular defense
mechanism
12.00 J. Villalba Interference of cell cycle checkpoint by quinone
reductase inhibitors.
12.20 J. Morrè CoQ/CoQH2 ratios from plasma membrane electron transport
ceramide
and shingosine-1-phosphate levels during GL arrest and apoptosis.
12.40 - 13.00 Discussion
13.00 - 14.30 Lunch
Plasma and tissue
concentrations
Chairpersons: GP Littarru and T. Menke
14.30 M. Miles Serum levels in children, adults and in metabolic syndrome
14.50 P. Palan Serum levels in pregnancy and menopause
15.10 T. Menke Measurement of CoQ10 in plasma and blood cells in
childhood: Age
related reference values, disease related changes and
comparison of values in
plasma and blood cells after oral supplementation
15.30 Lili Miles CoQ10 content of skeletal muscle
15.50 RB. Singh Effect of oral coenzymeQ10 dosages on serum Q10 and MDA
levels among healthy men.
16.10 - 16.30 Discussion
16.30 - 16.50 Coffee break
Effect of CoQ10 in gene expression
Chairpersons: C. Clarke and G. Dallner
16.50 D. Groneberg Coenzyme Q10 affects expression of genes involved in
cell signalling, metabolism and transport in human CaCo-2 cells
17.10 H. Nohl Ubiquinol and the papeverine derivative caroverin prevent
the
expression of tumor-promoting factors involved in
coloncarcinogenesis induced by
dietary-fat nutrition
17.30 -17.50 Discussion
17.50 - 18.30 Poster Session - R. Kalpravidh (beta-thalassemia), De
Luca-Korkina
(Coenzyme Q10 treatment in burns)
18.30 - 19.30 Meeting of participants involved in the Q-Symbio trial
Saturday, April 16th
Neuromuscular and neurodegenerative diseases
Chairpersons: C. Shults and A. Naini
8.30 F. Beal Preclinical Studies of CoQ in Neurodegenerative
Diseases and Clinical Trials
8.50 Geng Li Volume MRI Study: The effects of Coenzyme Q10 in
Transgenic Mouse Models of Alzheimer's Disease and Cerebral Ischemia
9.10 R. Artuch Familiar cerebellar ataxia caused by primary coenzyme Q10
deficiency
9.30 C. Shults Clinical Trials of Coenzyme Q10 in Neurological Diseases
9.50 Y. Yamamoto Redox status of CoQ in neurodegenerative syndromes
10.10-10.30 Discussion
10.30 -10.50 Coffee break
Role in aging mechanisms
Chairpersons: P. Navas and R. Sohal
10.50 R. Sohal Effects of coenzyme Q intake on the aging process
11.10 J. Quiles Coenzyme Q supplementation in aging
11.30 S. Hekimi Multiple ubiquinone-dependent processes as revealed by
clk-1 mutants
11.50 C. Santos Ocana Yeast YML125C, a Q-dependent PM reductase and
aging
control
12.10 -12.30 Discussion
12.30 - 14.30 Lunch break
Cardiovascular diseases
Chairpersons: SA. Mortensen and R. Belardinelli
14.30 B. Golomb Clinical follow-up after stopping statin treatment
14.50 P. Langsjoen Adverse consequences of HMG-CoA reductase inhibitors in
clinical cardiology and their response to supplemental CoQ10
15.10 M. Silver Lipitor/CoQ10/Diastolic Dysfunction study
15.30 H. Mabuchi Reduction of Serum Ubiquinol-10 and Ubiquinone-10 Levels
by
Atorvastatin in Hypercholesterolemic Patients
15.50 K. Adarsh Atorvastatin alone/in combination with coenzyme Q10 in 103
cases of
heart failure (HF) due to ischemic cardiomyopathy (ICM).
16.10 - 16.30 Discussion
16.30 - 16.50 Coffee break
Chairpersons: P. Langsjoen and B. Golomb
16.50 SA. Mortensen Q-Symbio study status
17.10 F. Rosenfeldt Metabolic, Physical and Mental preoperative approach
to surgery
17.30 R. Stocker Plasma CoQ10 concentration and cardiovascular disease
outcome
17.50 R. Belardinelli High-dose coenzymeQ10 improves the contractile
response to
dobutamine of dysfunctional myocardium in patients with ischemic
cardiomyopathy
18.10 - 18.30 Discussion
18.30 - 19.30 Poster session
20.00 Social dinner
Sunday, April 17th
Various clinical fields
Chairperson: Udo Hoppe and F. Beal
8.40 E. Teran Preeclampsia and CoQ10
9.00 A. Mancini CoQ10 levels in sperm cells and seminal plasma:
physiopathological implications
9.20 G. Balercia Treatment of idiopathic asthenozoospermia with coenzyme
Q10
9.40 Y. Ashida (Shiseido) CoQ10 intake elevates the epidermal CoQ10 level
in adult
hairless mice
10.00 T. Blatt (Beiersdorf) Stimulation of the Skin`s Energy Metabolism
Provides
Multiple Benefits
10.20-10.40 Discussion
10.40 -11.00 Coffee break
11.00 O. Gabrielli CoQ10 trial in Down syndrome
11.40 L. Korkina Coenzyme Q in treatment of the alkali-injured rabbit
cornea
12.0 J. Feher CoQ10 in combination with acetyl-L-carnitine and
omega -3 improves
age-related macular degeneration
12.20 Discussion and conclusions
13.00 Lunch